Abstract
BackgroundIn ph 2 studies, baricitinib (bari) improved disease activity with an acceptable safety profile in patients (pts) with active RA naïve to biologic DMARDs (bDMARDs).1,2ObjectivesTo report results from a ph...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have